Potential pitfalls of f-fdg pet in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation

Nuclear Medicine Communications

Volumn 26, Issue 8, 2005, Pages 689-694

  Castellucci, Paolo ^a   Nanni, Cristina ^b   Farsad, Mohsen ^b   Alinari, Lapo ^b   Zinzani, PierLuigi ^b   Stefoni, Vittorio ^b   Battista, Giuseppe ^b   Valentini, Daria ^b   Pettinato, Cinzia ^b   Marengo, Mario ^b   Boschi, Stefano ^b   Canini, Romeo ^b   Baccarani, Michele ^b   Monetti, Nino ^b   Franchi, Roberto ^b   Rampin, Lucia ^b   Fanti, Stefano ^b   Rubello, Domenico ^b  

^a AO S Orsola Malpighi   (Italy)

^b Nuclear Medicine Service   (Italy)

Author keywords

Malignant lymphoma; PET; Potential pitfalls

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ARTIFACT; DIAGNOSTIC ERROR; HUMAN; LYMPHOMA; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME; ABSCESS; ADULT; COLITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTRITIS; HERPES ZOSTER; HUMAN TISSUE; LACTATION; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MUSCLE CONTRACTION; THYMUS HYPERPLASIA;

ARTIFACTS; DIAGNOSTIC ERRORS; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 23044478389     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000171781.11027.bb     Document Type: Article

References (21)

1. O'Doherty MJ, Hoskin PJ. Positron emission tomography in the management of lymphomas: a summary. Eur J Nucl Med Mol Imaging 2003; 30(suppl 1):S128-S130.
2. Hoskin PJ. PET in lymphoma: what are the oncologist's needs. Eur J Nucl Med Mol Imaging 2003; 30(suppl 1):S37-S41.
3. Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, et al. 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol 2002; 4:104-114.
4. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43:1018-1027.
5. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1356-1363.
6. 18F-FDG in Hodgkin's disease for post-treatment evaluation. J Nucl Med 2003; 44:1225-1231.
7. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930-2934.
8. Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, Hallahan DE. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57:307-315.
9. 18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115:272-278.
10. Romer W, Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imaging 1998; 1:101-110.
11. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27:1564-1578.
12. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; 30(suppl 1):S117-S127.
13. 18F-FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30:682-688.
14. Boomanji JB, Syed R, Brock C, Jankowska P, Dogan A, Costa DC, et al. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease. J Clin Oncol 2002; 20:3347-3349.
15. Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J. False positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997; 38:888-890.
16. 18F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003; 44:1789-1796.
17. 18F-FDG PET imaging. Anticancer Res 2003; 23:2941-2944.
18. Cabrera Villegas A, Canovas Fernandez A, Martin Urreta JC. Post-radiation pneumonitis in a case of Hodgkin's lymphoma assessed with PET-FDG by residual mediastinic mass. Rev Esp Med Nucl 2000; 19:288-292.
19. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61-77.
20. Strauss LG. Fluorine-18 deoxyglucose and false positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23:1409-1415.
21. Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, et al. Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001; 12:719-722.